Tags

Type your tag names separated by a space and hit enter

A Case Report on Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response.
Neuropediatrics 2015; 46(4):292-5N

Abstract

Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system and preferentially targets the optic nerves and spinal cord. NMO is rare in children and clinical course of the disease is highly variable as described in studies. Here, we present a case report of a young girl presenting with a rare course of pediatric NMO with an early disease onset at the age of 12 years, a relapse free interval of 4 years, evidence of NMO immunoglobulin G (IgG) and an unusual response against immunosuppressive therapy. The aim of this report is to highlight the potentially long remission period between relapses complicating proper diagnosis despite well defined diagnostic criteria. In addition, we want to encourage the use of rituximab in pediatric NMO, although larger cohorts are warranted to establish B cell depleting therapies in juvenile NMO.

Authors+Show Affiliations

University Children's Hospital Muenster, General Pediatrics-Neuropediatric Department, University of Muenster, Muenster, Germany.Department of Neurology, University of Muenster, Muenster, Germany.University Children's Hospital Muenster, General Pediatrics-Neuropediatric Department, University of Muenster, Muenster, Germany.Department of Neurology, University of Muenster, Muenster, Germany.University Children's Hospital Muenster, General Pediatrics-Neuropediatric Department, University of Muenster, Muenster, Germany.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

26058738

Citation

Elpers, Christiane, et al. "A Case Report On Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response." Neuropediatrics, vol. 46, no. 4, 2015, pp. 292-5.
Elpers C, Gross CC, Fiedler B, et al. A Case Report on Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response. Neuropediatrics. 2015;46(4):292-5.
Elpers, C., Gross, C. C., Fiedler, B., Meuth, S. G., & Kurlemann, G. (2015). A Case Report on Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response. Neuropediatrics, 46(4), pp. 292-5. doi:10.1055/s-0035-1554101.
Elpers C, et al. A Case Report On Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response. Neuropediatrics. 2015;46(4):292-5. PubMed PMID: 26058738.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Case Report on Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response. AU - Elpers,Christiane, AU - Gross,Catharina C, AU - Fiedler,Barbara, AU - Meuth,Sven G, AU - Kurlemann,Gerhard, Y1 - 2015/06/09/ PY - 2015/6/11/entrez PY - 2015/6/11/pubmed PY - 2016/4/9/medline SP - 292 EP - 5 JF - Neuropediatrics JO - Neuropediatrics VL - 46 IS - 4 N2 - Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the central nervous system and preferentially targets the optic nerves and spinal cord. NMO is rare in children and clinical course of the disease is highly variable as described in studies. Here, we present a case report of a young girl presenting with a rare course of pediatric NMO with an early disease onset at the age of 12 years, a relapse free interval of 4 years, evidence of NMO immunoglobulin G (IgG) and an unusual response against immunosuppressive therapy. The aim of this report is to highlight the potentially long remission period between relapses complicating proper diagnosis despite well defined diagnostic criteria. In addition, we want to encourage the use of rituximab in pediatric NMO, although larger cohorts are warranted to establish B cell depleting therapies in juvenile NMO. SN - 1439-1899 UR - https://www.unboundmedicine.com/medline/citation/26058738/A_Case_Report_on_Juvenile_Neuromyelitis_Optica:_Early_Onset_Long_Remission_Period_and_Atypical_Treatment_Response_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0035-1554101 DB - PRIME DP - Unbound Medicine ER -